Your browser doesn't support javascript.
loading
Elevated IFNA1 and suppressed IL12p40 associated with persistent hyperinflammation in COVID-19 pneumonia.
Jeon, Kyeongseok; Kim, Yuri; Kang, Shin Kwang; Park, Uni; Kim, Jayoun; Park, Nanhee; Koh, Jaemoon; Shim, Man-Shik; Kim, Minsoo; Rhee, Youn Ju; Jeong, Hyeongseok; Lee, Siyoung; Park, Donghyun; Lim, Jinyoung; Kim, Hyunsu; Ha, Na-Young; Jo, Hye-Yeong; Kim, Sang Cheol; Lee, Ju-Hee; Shon, Jiwon; Kim, Hoon; Jeon, Yoon Kyung; Choi, Youn-Soo; Kim, Hye Young; Lee, Won-Woo; Choi, Murim; Park, Hyun-Young; Park, Woong-Yang; Kim, Yeon-Sook; Cho, Nam-Hyuk.
Affiliation
  • Jeon K; Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim Y; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kang SK; Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Park U; Department of Thoracic and Cardiovascular Surgery, Chungnam National University School of Medicine, Deajon, Republic of Korea.
  • Kim J; Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Park N; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Koh J; Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea.
  • Shim MS; Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea.
  • Kim M; Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Rhee YJ; Department of Thoracic and Cardiovascular Surgery, Chungnam National University School of Medicine, Deajon, Republic of Korea.
  • Jeong H; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Lee S; Department of Thoracic and Cardiovascular Surgery, Chungnam National University School of Medicine, Deajon, Republic of Korea.
  • Park D; Department of Internal Medicine, Chungnam National University School of Medicine, Deajon, Republic of Korea.
  • Lim J; Geninus Inc., Seoul, Republic of Korea.
  • Kim H; Geninus Inc., Seoul, Republic of Korea.
  • Ha NY; Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea.
  • Jo HY; Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea.
  • Kim SC; Chungnam National University Hospital, Biomedical Research Institute, Deajon, Republic of Korea.
  • Lee JH; Division of Healthcare and Artificial Intelligence, Department of Precision Medicine, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
  • Shon J; Division of Healthcare and Artificial Intelligence, Department of Precision Medicine, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
  • Kim H; Division of Healthcare and Artificial Intelligence, Department of Precision Medicine, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
  • Jeon YK; Department of Biohealth Regulatory Science, School of Pharmacy, Sungkyunkwan University, Suwon-si, Gyeonggi-do, Republic of Korea.
  • Choi YS; Department of Biohealth Regulatory Science, School of Pharmacy, Sungkyunkwan University, Suwon-si, Gyeonggi-do, Republic of Korea.
  • Kim HY; Biopharmaceutical Convergence Major, School of Pharmacy, Sungkyunkwan University, Suwon-si, Gyeonggi-do, Republic of Korea.
  • Lee WW; Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Choi M; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Park HY; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Park WY; Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim YS; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Cho NH; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
Front Immunol ; 14: 1101808, 2023.
Article in En | MEDLINE | ID: mdl-36776879
ABSTRACT

Introduction:

Despite of massive endeavors to characterize inflammation in COVID-19 patients, the core network of inflammatory mediators responsible for severe pneumonia stillremain remains elusive.

Methods:

Here, we performed quantitative and kinetic analysis of 191 inflammatory factors in 955 plasma samples from 80 normal controls (sample n = 80) and 347 confirmed COVID-19 pneumonia patients (sample n = 875), including 8 deceased patients.

Results:

Differential expression analysis showed that 76% of plasmaproteins (145 factors) were upregulated in severe COVID-19 patients comparedwith moderate patients, confirming overt inflammatory responses in severe COVID-19 pneumonia patients. Global correlation analysis of the plasma factorsrevealed two core inflammatory modules, core I and II, comprising mainly myeloid cell and lymphoid cell compartments, respectively, with enhanced impact in a severity-dependent manner. We observed elevated IFNA1 and suppressed IL12p40, presenting a robust inverse correlation in severe patients, which was strongly associated with persistent hyperinflammation in 8.3% of moderate pneumonia patients and 59.4% of severe patients.

Discussion:

Aberrant persistence of pulmonary and systemic inflammation might be associated with long COVID-19 sequelae. Our comprehensive analysis of inflammatory mediators in plasmarevealed the complexity of pneumonic inflammation in COVID-19 patients anddefined critical modules responsible for severe pneumonic progression.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article